<!doctype html>

<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Research • Stanfield Lab</title>
  <meta name="description" content="Stanfield Lab at LSU SVM: Developing guinea pig models for preclinical cancer drug and vaccine development.">
  <link rel="icon" href="assets/favicon.svg" type="image/svg+xml">
  <style>
    :root {
      --primary-blue: #0ea5e9;
      --primary-green: #10b981;
      --text-dark: #0f172a;
      --text-muted: #64748b;
      --bg-light: #f8fafc;
      --bg-card: #ffffff;
      --border-color: #e2e8f0;
      --shadow-md: 0 4px 6px -1px rgb(0 0 0 / 0.1);
      --accent-orange: #f59e0b;
      --accent-purple: #8b5cf6;
    }

```
* { box-sizing: border-box; }

body {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
  line-height: 1.6;
  color: var(--text-dark);
  background-color: var(--bg-light);
  margin: 0;
  padding: 0;
}

.container {
  max-width: 1200px;
  margin: 0 auto;
  padding: 0 1rem;
}

.site-header {
  background: var(--bg-card);
  border-bottom: 1px solid var(--border-color);
  box-shadow: 0 1px 3px 0 rgb(0 0 0 / 0.1);
  position: sticky;
  top: 0;
  z-index: 1000;
}

.header-wrap {
  display: flex;
  align-items: center;
  justify-content: space-between;
  padding: 1rem;
}

.brand {
  display: flex;
  align-items: center;
  text-decoration: none;
  color: var(--text-dark);
  font-weight: 700;
  font-size: 1.25rem;
}

.brand-img { height: 40px; margin-right: 0.5rem; }

nav { display: flex; align-items: center; }

.nav-toggle {
  display: none;
  background: none;
  border: none;
  font-size: 1rem;
  padding: 0.5rem;
  cursor: pointer;
}

.nav-list {
  display: flex;
  list-style: none;
  margin: 0;
  padding: 0;
  gap: 2rem;
}

.nav-list a {
  text-decoration: none;
  color: var(--text-dark);
  font-weight: 500;
  padding: 0.5rem 1rem;
  border-radius: 0.5rem;
  transition: all 0.2s;
}

.nav-list a:hover,
.nav-list a[aria-current="page"] {
  background-color: var(--bg-light);
  color: var(--primary-blue);
}

.theme-toggle {
  background: none;
  border: 1px solid var(--border-color);
  border-radius: 0.5rem;
  padding: 0.5rem;
  margin-left: 1rem;
  cursor: pointer;
  font-size: 1.2rem;
}

main { padding: 2rem 0; }

h1 {
  font-size: 3rem;
  font-weight: 800;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  background-clip: text;
  margin-bottom: 2rem;
  text-align: center;
}

h2 {
  font-size: 2rem;
  font-weight: 700;
  color: var(--text-dark);
  margin: 3rem 0 1.5rem 0;
  position: relative;
}

h2::after {
  content: '';
  position: absolute;
  bottom: -0.5rem;
  left: 0;
  width: 4rem;
  height: 3px;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  border-radius: 2px;
}

p {
  font-size: 1.05rem;
  line-height: 1.7;
  margin-bottom: 1.5rem;
}

.checklist {
  list-style: none;
  padding: 0;
  margin: 2rem 0;
}

.checklist li {
  background: var(--bg-card);
  border-radius: 0.75rem;
  padding: 1.5rem;
  margin-bottom: 1.5rem;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
  position: relative;
  transition: transform 0.2s ease;
  padding-left: 4rem;
}

.checklist li:hover { transform: translateY(-2px); }

.checklist li::before {
  content: '✓';
  position: absolute;
  left: 1.5rem;
  top: 1.5rem;
  color: var(--primary-green);
  font-weight: bold;
  font-size: 1.2rem;
}

.checklist li strong {
  color: var(--primary-blue);
  font-size: 1.1rem;
  display: block;
  margin-bottom: 0.5rem;
}

/* Diagram block */
.research-graphic {
  margin: 3rem auto;
  background: var(--bg-card);
  border-radius: 1rem;
  padding: 2rem;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
  position: relative;
}

.research-graphic h3 {
  font-size: 1.5rem;
  font-weight: 700;
  color: var(--primary-blue);
  margin: 0 0 1rem 0;
  text-align: center;
}

.static-svg {
  width: 100%;
  height: auto;
  display: block;
  margin: 0 auto;
}

.diagram-caption {
  background: var(--bg-light);
  border-radius: 0.5rem;
  padding: 1rem;
  margin-top: 1rem;
  text-align: center;
  font-size: 0.95rem;
  line-height: 1.5;
  color: var(--text-muted);
}

/* Research Impact / comparison */
.research-impact, .model-comparison {
  background: var(--bg-card);
  border-radius: 1rem;
  padding: 2rem;
  margin: 3rem 0;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
}

.impact-grid {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
  gap: 2rem;
  margin-top: 2rem;
}

.impact-card {
  background: var(--bg-light);
  border-radius: 0.75rem;
  padding: 1.5rem;
  text-align: center;
  transition: transform 0.2s ease;
}

.impact-card:hover { transform: translateY(-2px); }

.impact-number {
  font-size: 3rem;
  font-weight: 800;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  background-clip: text;
  display: block;
  margin-bottom: 0.5rem;
}

.impact-label { font-size: 1rem; color: var(--text-muted); font-weight: 500; }

.comparison-chart { margin: 2rem 0; }
.comparison-item { display: flex; align-items: center; margin: 1rem 0; padding: 1rem; background: var(--bg-light); border-radius: 0.5rem; }
.comparison-label { flex: 0 0 200px; font-weight: 600; color: var(--text-dark); }
.comparison-bars { flex: 1; display: flex; gap: 1rem; align-items: center; }
.comparison-bar { height: 24px; border-radius: 12px; display: flex; align-items: center; justify-content: center; color: white; font-size: 0.8rem; font-weight: 600; min-width: 60px; transition: transform 0.2s ease; }
.comparison-bar:hover { transform: scale(1.05); }
.bar-human { background: var(--primary-blue); }
.bar-guinea-pig { background: var(--primary-green); }
.bar-mouse { background: var(--text-muted); }

/* Motion & a11y */
.skip-link {
  position: absolute;
  top: -40px;
  left: 6px;
  background: var(--text-dark);
  color: white;
  padding: 8px;
  text-decoration: none;
  border-radius: 4px;
  z-index: 1001;
}
.skip-link:focus { top: 6px; }

.fade-in { opacity: 0; transform: translateY(20px); transition: all 0.6s ease; }
.fade-in.visible { opacity: 1; transform: translateY(0); }

/* Footer */
.site-footer { background: var(--text-dark); color: white; padding: 3rem 0 1rem; margin-top: 4rem; }
.footer-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 2rem; margin-bottom: 2rem; }
.footer-brand { display: flex; align-items: center; gap: 1rem; }
.footer-logo { height: 48px; }
.footer-brand h3 { margin: 0; font-size: 1.5rem; }
.footer-brand p { margin: 0.5rem 0 0 0; color: #94a3b8; font-size: 0.875rem; }
.footer-grid h4 { margin-bottom: 1rem; color: #e2e8f0; }
.footer-grid a { color: #94a3b8; text-decoration: none; }
.footer-grid a:hover { color: white; }
.footer-bottom { border-top: 1px solid #374151; padding-top: 1rem; text-align: center; color: #94a3b8; font-size: 0.875rem; }

/* Responsive */
@media (max-width: 768px) {
  .nav-toggle { display: block; }
  .nav-list {
    display: none; position: absolute; top: 100%; left: 0; right: 0; background: var(--bg-card);
    flex-direction: column; box-shadow: var(--shadow-md); border-top: 1px solid var(--border-color);
    padding: 1rem; gap: 0.5rem;
  }
  .nav-list.active { display: flex; }
  h1 { font-size: 2rem; }
  h2 { font-size: 1.5rem; }
  .research-graphic { padding: 1rem; margin: 2rem auto; }
  .impact-grid { grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); }
  .comparison-item { flex-direction: column; gap: 1rem; }
  .comparison-label { flex: none; text-align: center; }
  .comparison-bars { justify-content: center; }
}

@media (max-width: 480px) {
  .container { padding: 0 0.5rem; }
  .research-graphic { padding: 0.5rem; }
}

@media print {
  .site-header, .site-footer, .nav-toggle, .theme-toggle { display: none; }
  .research-graphic { break-inside: avoid; }
}
```

  </style>
</head>
<body>
  <a class="skip-link" href="#main">Skip to content</a>

  <header class="site-header" role="banner">
    <div class="container header-wrap">
      <a class="brand" href="index.html" aria-label="Stanfield Lab home">
        <img src="assets/stanfield-lab-logo.svg" alt="Stanfield Lab" class="brand-img">
      </a>
      <nav aria-label="Primary">
        <button id="navToggle" class="nav-toggle" aria-expanded="false" aria-controls="primaryNav">☰ Menu</button>
        <ul id="primaryNav" class="nav-list">
          <li><a href="index.html">Home</a></li>
          <li><a href="research.html" aria-current="page">Research</a></li>
          <li><a href="people.html">People</a></li>
          <li><a href="publications.html">Publications</a></li>
          <li><a href="news.html">News</a></li>
          <li><a href="opportunities.html">Opportunities</a></li>
          <li><a href="contact.html">Contact</a></li>
        </ul>
      </nav>
      <button id="themeToggle" class="theme-toggle" aria-label="Toggle dark mode">◐</button>
    </div>
  </header>

  <main id="main" class="container">
    <h1 class="fade-in">Research</h1>

```
<p class="fade-in">
  The Stanfield Lab investigates how oncogenic viruses initiate infection,
  evade host defenses, and drive cancer development. Our central mission is to
  create and refine <strong>immune-competent guinea pig models</strong> that bridge
  the gap between basic virology and translational medicine. By combining primary
  cell culture, in vivo pathogenesis studies, and advanced genomics, we aim to
  uncover how viruses such as <strong>Kaposi's sarcoma–associated herpesvirus (KSHV)</strong>,
  <strong>Epstein–Barr virus (EBV)</strong>, and <strong>Human papillomavirus (HPV)</strong> 
  establish infection and promote tumorigenesis.
</p>

<p class="fade-in">
  Guinea pigs provide a uniquely valuable system: their immune and physiological
  responses often parallel those of humans more closely than traditional murine
  models. We leverage this platform to model virus–host interactions, test
  therapeutic strategies, and expand the toolkit for studying host-restricted
  pathogens that have lacked tractable small-animal models. Our work spans from
  <strong>herpesvirus-associated lymphomas and sarcomas to HPV-driven cervical 
  cancers</strong>, providing comprehensive models for viral oncology research.
</p>

<!-- Impact -->
<section class="research-impact fade-in">
  <h2>Research Impact</h2>
  <p>Our guinea pig models are advancing viral oncology across herpesvirus and papillomavirus-associated cancers, providing new tools for preclinical drug and vaccine development.</p>
</section>

<h2 class="fade-in">Current focus areas</h2>
<ul class="checklist fade-in">
  <li><strong>Innate sensing and viral evasion.</strong> Defining how KSHV activates and subverts the <em>IRF7</em>, <em>MDA5</em>, and RIG-I pathways in guinea pig cells, and identifying viral genes that interfere with these sensors.</li>
  <li><strong>Endothelial infection and tumorigenesis.</strong> Establishing cultures of guinea pig endothelial cells and modeling how KSHV-driven transformation leads to vascularized tumors, both in immunodeficient mice and in immunosuppressed strain 2 guinea pigs.</li>
  <li><strong>HPV therapeutic vaccine development.</strong> Developing and testing therapeutic vaccines against HPV-associated cervical cancer using existing syngeneic mouse models while creating novel syngeneic guinea pig models that better recapitulate human disease.</li>
  <li><strong>Syngeneic guinea pig cervical cancer models.</strong> Engineering and characterizing new guinea pig models of HPV-associated cervical cancer for enhanced vaccine and therapeutic testing.</li>
  <li><strong>Syngeneic lymphoma model.</strong> Characterizing the L2C guinea pig lymphoma line with genomics and single-cell RNA-seq and positioning it as an analog for mantle cell lymphoma and CLL.</li>
  <li><strong>Comparative virology and viral adaptation.</strong> Studying related herpesviruses (RRV, GPHLV, GPXV) to guide engineering of guinea pig–adapted EBV and KSHV.</li>
  <li><strong>Preclinical testing platform.</strong> Evaluating antivirals, vaccines, epigenetic modulators, and targeted therapies (e.g., BTK inhibitors) across our models.</li>
  <li><strong>Single-cell and systems approaches.</strong> Applying scRNA-seq and pathway analysis to map viral/host programs and therapeutic responses in vivo.</li>
</ul>

<!-- ======================================== -->
<!-- Diagram 1: Innate Immune Signaling -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>Innate Immune Signaling: Guinea Pig vs Human Responses to KSHV</h3>
  <svg class="static-svg" viewBox="0 0 1180 600" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Innate sensing via MDA5/MAVS/IRF7 in guinea pig vs human with KSHV antagonism">
    <defs>
      <marker id="arrG" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <marker id="arrN" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#9aa3af"/></marker>
      <marker id="tbar" viewBox="0 0 12 12" refX="2" refY="6" markerWidth="8" markerHeight="8" orient="auto"><path d="M2 0V12" stroke="#ef4444" stroke-width="3"/></marker>
      <filter id="soft"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="295" y="36" text-anchor="middle" font-size="26" font-weight="700" fill="#0f172a">Guinea Pig — Activated</text>
    <text x="885" y="36" text-anchor="middle" font-size="26" font-weight="700" fill="#0f172a">Human — Suppressed by KSHV</text>
    <rect x="40"  y="56" width="510" height="420" rx="20" fill="#ecfeff" stroke="#93c5fd" filter="url(#soft)"/>
    <rect x="630" y="56" width="510" height="420" rx="20" fill="#f8fafc" stroke="#cbd5e1" filter="url(#soft)"/>
    <line x1="600" y1="56" x2="600" y2="476" stroke="#cbd5e1"/>
    <!-- LEFT -->
    <g>
      <rect x="70" y="90" width="130" height="40" rx="10" fill="#e0f2fe" stroke="#0ea5e9"/><text x="135" y="115" text-anchor="middle" font-weight="700" fill="#075985">dsRNA (viral)</text>
      <rect x="230" y="90" width="120" height="40" rx="12" fill="#dcfce7" stroke="#10b981"/><text x="290" y="115" text-anchor="middle" font-weight="700" fill="#065f46">MDA5</text>
      <rect x="230" y="170" width="120" height="40" rx="12" fill="#dcfce7" stroke="#10b981"/><text x="290" y="195" text-anchor="middle" font-weight="700" fill="#065f46">MAVS</text>
      <rect x="230" y="250" width="120" height="40" rx="12" fill="#dcfce7" stroke="#10b981"/><text x="290" y="275" text-anchor="middle" font-weight="700" fill="#065f46">IRF7</text>
      <rect x="230" y="330" width="120" height="40" rx="12" fill="#10b981" stroke="#059669"/><text x="290" y="355" text-anchor="middle" font-weight="700" fill="#fff">Type I IFN</text>
      <line x1="200" y1="110" x2="230" y2="110" stroke="#10b981" stroke-width="5" marker-end="url(#arrG)"/>
      <line x1="290" y1="130" x2="290" y2="170" stroke="#10b981" stroke-width="5" marker-end="url(#arrG)"/>
      <line x1="290" y1="210" x2="290" y2="250" stroke="#10b981" stroke-width="5" marker-end="url(#arrG)"/>
      <line x1="290" y1="290" x2="290" y2="330" stroke="#10b981" stroke-width="5" marker-end="url(#arrG)"/>
      <rect x="370" y="88" width="160" height="64" rx="10" fill="#ecfeff" stroke="#22d3ee"/>
      <text x="450" y="108" text-anchor="middle" font-size="13" fill="#155e75">KSHV miRNAs</text>
      <text x="450" y="126" text-anchor="middle" font-size="12" fill="#155e75">seed mismatch in gpIFIH1</text>
      <text x="450" y="142" text-anchor="middle" font-size="12" fill="#155e75">→ weak MDA5 repression</text>
      <line x1="370" y1="120" x2="350" y2="120" stroke="#22d3ee" stroke-width="3" marker-end="url(#arrN)"/>
      <rect x="370" y="248" width="160" height="64" rx="10" fill="#ecfeff" stroke="#22d3ee"/>
      <text x="450" y="268" text-anchor="middle" font-size="13" fill="#155e75">K10.5 (vIRF-3)</text>
      <text x="450" y="286" text-anchor="middle" font-size="12" fill="#155e75">interface changes in gpIRF7</text>
      <text x="450" y="302" text-anchor="middle" font-size="12" fill="#155e75">→ poor inhibition</text>
      <line x1="370" y1="280" x2="350" y2="270" stroke="#22d3ee" stroke-width="3" marker-end="url(#arrN)"/>
      <rect x="70" y="170" width="130" height="40" rx="10" fill="#f1f5f9" stroke="#cbd5e1"/>
      <text x="135" y="195" text-anchor="middle" font-weight="700" fill="#475569">RIG-I (minor)</text>
      <line x1="200" y1="190" x2="230" y2="190" stroke="#9aa3af" stroke-width="3" marker-end="url(#arrN)"/>
    </g>
    <!-- RIGHT -->
    <g>
      <rect x="660" y="90" width="120" height="40" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/><text x="720" y="115" text-anchor="middle" font-weight="700" fill="#374151">MDA5</text>
      <rect x="660" y="170" width="120" height="40" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/><text x="720" y="195" text-anchor="middle" font-weight="700" fill="#374151">MAVS</text>
      <rect x="660" y="250" width="120" height="40" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/><text x="720" y="275" text-anchor="middle" font-weight="700" fill="#374151">IRF7</text>
      <rect x="660" y="330" width="120" height="40" rx="12" fill="#d1d5db" stroke="#cbd5e1"/><text x="720" y="355" text-anchor="middle" font-weight="700" fill="#111827">Type I IFN ↓</text>
      <line x1="620" y1="110" x2="660" y2="110" stroke="#9aa3af" stroke-width="5" marker-end="url(#arrN)"/>
      <line x1="720" y1="130" x2="720" y2="170" stroke="#9aa3af" stroke-width="5" marker-end="url(#arrN)"/>
      <line x1="720" y1="210" x2="720" y2="250" stroke="#9aa3af" stroke-width="5" marker-end="url(#arrN)"/>
      <line x1="720" y1="290" x2="720" y2="330" stroke="#9aa3af" stroke-width="5" marker-end="url(#arrN)"/>
      <rect x="820" y="88" width="180" height="64" rx="10" fill="#fee2e2" stroke="#ef4444"/>
      <text x="910" y="108" text-anchor="middle" font-weight="700" fill="#991b1b">KSHV miRNAs</text>
      <text x="910" y="126" text-anchor="middle" font-size="12" fill="#991b1b">target IFIH1 (MDA5) mRNA</text>
      <line x1="820" y1="120" x2="780" y2="120" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
      <rect x="820" y="248" width="180" height="64" rx="10" fill="#fee2e2" stroke="#ef4444"/>
      <text x="910" y="268" text-anchor="middle" font-weight="700" fill="#991b1b">K10.5 (vIRF-3)</text>
      <text x="910" y="286" text-anchor="middle" font-size="12" fill="#991b1b">binds & inhibits IRF7</text>
      <line x1="820" y1="280" x2="780" y2="270" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
      <rect x="820" y="330" width="180" height="40" rx="10" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="910" y="355" text-anchor="middle" fill="#334155" font-size="13">IFN signaling dampened</text>
    </g>
    <g>
      <rect x="40" y="500" width="1100" height="70" rx="12" fill="#f1f5f9" stroke="#cbd5e1"/>
      <text x="60" y="522" font-weight="700" fill="#0f172a">Summary:</text>
      <text x="60" y="542" fill="#334155" font-size="12">
        In guinea pig cells, MDA5→MAVS→IRF7 remains active (putative miRNA seed mismatches; weaker vIRF-3:IRF7 binding). In human cells, KSHV miRNAs repress IFIH1 transcripts and vIRF-3 blocks IRF7, reducing type I IFN.
      </text>
    </g>
  </svg>
  <div class="diagram-caption">
    Guinea pig cells show enhanced MDA5→MAVS→IRF7 activation; in human cells KSHV miRNAs (targeting IFIH1) and vIRF-3 suppression of IRF7 dampen IFN responses.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 2: KSHV Endothelial Transformation -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>KSHV Endothelial Cell Transformation and Kaposi's Sarcoma Development</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="KSHV endothelial transformation with entry receptors, signaling, latency genes, and angiogenic drivers">
    <defs>
      <marker id="arrBlue" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#0ea5e9"/></marker>
      <marker id="arrRed"  viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrGreen" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <filter id="soft2"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">KSHV Endothelial Transformation</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Entry ➜ Acute signaling ➜ Latency modules ➜ Paracrine/angiogenic output ➜ KS-like lesion</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft2)"/>
    <g>
      <rect x="70" y="110" width="300" height="110" rx="12" fill="#eef2ff" stroke="#6366f1"/>
      <text x="220" y="132" text-anchor="middle" font-size="16" font-weight="700" fill="#3730a3">Entry & Attachment</text>
      <text x="220" y="150" text-anchor="middle" font-size="12" fill="#3730a3">Heparan sulfate (HS)</text>
      <text x="220" y="166" text-anchor="middle" font-size="12" fill="#3730a3">Integrins αVβ3 / α3β1 • EphA2</text>
      <text x="220" y="182" text-anchor="middle" font-size="12" fill="#3730a3">DC-SIGN / xCT (context-dependent)</text>
      <g fill="#2563eb" stroke="#1e3a8a" stroke-width="2">
        <circle cx="95" cy="190" r="10"/><circle cx="130" cy="195" r="10"/><circle cx="165" cy="188" r="10"/>
      </g>
      <line x1="185" y1="195" x2="210" y2="205" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlue)"/>
    </g>
    <g>
      <rect x="390" y="110" width="300" height="110" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="540" y="132" text-anchor="middle" font-size="16" font-weight="700" fill="#075985">Acute Signaling</text>
      <text x="540" y="150" text-anchor="middle" font-size="12" fill="#075985">FAK/Src ➜ PI3K–AKT, MAPK/ERK</text>
      <text x="540" y="166" text-anchor="middle" font-size="12" fill="#075985">NF-κB activation • Survival/entry</text>
      <line x1="370" y1="165" x2="390" y2="165" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrBlue)"/>
    </g>
    <g>
      <rect x="710" y="110" width="400" height="160" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="910" y="132" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Latency & Transformation Modules</text>
      <rect x="730" y="145" width="110" height="34" rx="10" fill="#fef3c7" stroke="#f59e0b"/><text x="785" y="167" text-anchor="middle" font-weight="700" fill="#92400e">LANA</text>
      <text x="785" y="182" text-anchor="middle" font-size="11" fill="#92400e">episome; p53/RB</text>
      <rect x="850" y="145" width="130" height="34" rx="10" fill="#e0f2fe" stroke="#0ea5e9"/><text x="915" y="167" text-anchor="middle" font-weight="700" fill="#075985">vCyclin–CDK6</text>
      <rect x="990" y="145" width="100" height="34" rx="10" fill="#fee2e2" stroke="#ef4444"/><text x="1040" y="167" text-anchor="middle" font-weight="700" fill="#991b1b">vFLIP</text>
      <text x="1040" y="182" text-anchor="middle" font-size="11" fill="#991b1b">NF-κB</text>
      <rect x="730" y="190" width="130" height="34" rx="10" fill="#eef2ff" stroke="#6366f1"/><text x="795" y="212" text-anchor="middle" font-weight="700" fill="#3730a3">KSHV miRNAs</text>
      <rect x="870" y="190" width="90" height="34" rx="10" fill="#dcfce7" stroke="#10b981"/><text x="915" y="212" text-anchor="middle" font-weight="700" fill="#065f46">K1 (PI3K)</text>
      <rect x="970" y="190" width="120" height="34" rx="10" fill="#fef3c7" stroke="#f59e0b"/><text x="1030" y="212" text-anchor="middle" font-weight="700" fill="#92400e">Episome (latency)</text>
      <line x1="690" y1="165" x2="710" y2="165" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrBlue)"/>
    </g>
    <g>
      <rect x="70" y="250" width="360" height="110" rx="12" fill="#fff7ed" stroke="#fb923c"/>
      <text x="250" y="272" text-anchor="middle" font-size="16" font-weight="700" fill="#9a3412">Paracrine / Angiogenic Drivers</text>
      <rect x="90"  y="286" width="110" height="34" rx="10" fill="#fef3c7" stroke="#f59e0b"/><text x="145" y="308" text-anchor="middle" font-weight="700" fill="#92400e">vIL-6</text>
      <rect x="210" y="286" width="130" height="34" rx="10" fill="#fef3c7" stroke="#f59e0b"/><text x="275" y="308" text-anchor="middle" font-weight="700" fill="#92400e">vGPCR (ORF74)</text>
      <rect x="350" y="286" width="60" height="34" rx="10" fill="#fee2e2" stroke="#ef4444"/><text x="380" y="308" text-anchor="middle" font-weight="700" fill="#991b1b">VEGF</text>
      <line x1="430" y1="303" x2="470" y2="303" stroke="#fb923c" stroke-width="4" marker-end="url(#arrRed)"/>
    </g>
    <g>
      <rect x="470" y="250" width="330" height="110" rx="12" fill="#ffe4e6" stroke="#fb7185"/>
      <text x="635" y="272" text-anchor="middle" font-size="16" font-weight="700" fill="#9f1239">KS-like spindle cell lesion</text>
      <text x="635" y="292" text-anchor="middle" font-size="12" fill="#9f1239">endothelial origin • vascularized</text>
      <text x="635" y="308" text-anchor="middle" font-size="12" fill="#9f1239">inflammation • immune modulation</text>
      <line x1="420" y1="303" x2="470" y2="303" stroke="#ef4444" stroke-width="4" marker-end="url(#arrRed)"/>
    </g>
    <g>
      <rect x="820" y="250" width="320" height="110" rx="12" fill="#f1f5f9" stroke="#cbd5e1"/>
      <text x="980" y="272" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Hallmarks in KS Endothelium</text>
      <text x="980" y="294" text-anchor="middle" font-size="12" fill="#334155">Angiogenesis (VEGF/HIF-1α)</text>
      <text x="980" y="310" text-anchor="middle" font-size="12" fill="#334155">Proliferation (vCyclin–CDK6)</text>
      <text x="980" y="326" text-anchor="middle" font-size="12" fill="#334155">NF-κB survival & immune evasion (vFLIP, miRNAs)</text>
    </g>
    <line x1="1040" y1="224" x2="1040" y2="250" stroke="#ef4444" stroke-width="4" marker-end="url(#arrRed)"/>
    <line x1="915"  y1="180" x2="915"  y2="250" stroke="#ef4444" stroke-width="4" marker-end="url(#arrRed)"/>
    <g>
      <rect x="40" y="620" width="1100" height="60" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">What's known:</text>
      <text x="60" y="660" fill="#334155" font-size="12">HS + Integrins + EphA2 mediate entry → FAK/Src→PI3K–AKT, MAPK, NF-κB. Latency genes LANA, vCyclin–CDK6, vFLIP, K1 and KSHV miRNAs remodel the cell. Paracrine vIL-6 & vGPCR amplify VEGF/angiogenesis, producing KS-like vascular lesions.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    Modular overview of endothelial transformation: entry, acute signaling, latency programs, and paracrine/angiogenic outputs that drive KS-like lesions.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 3: HPV -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>HPV Cervical Cancer Progression and Therapeutic Vaccine Strategy</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="HPV infection and E6/E7 oncoprotein-driven progression from CIN to invasive cancer with therapeutic vaccination">
    <defs>
      <marker id="arrPurple" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
      <marker id="arrOrange" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
      <marker id="arrRedH" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrBlueH" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
      <marker id="arrGreenH" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <filter id="soft3"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">HPV Cervical Cancer & Therapeutic Vaccines</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Normal cervix → HPV infection → E6/E7 expression → CIN progression → invasive cancer + vaccine intervention</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft3)"/>
    <!-- Normal Cervical Epithelium -->
    <g>
      <rect x="70" y="400" width="160" height="120" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="150" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Normal</text>
      <text x="150" y="445" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Cervical</text>
      <text x="150" y="465" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Epithelium</text>
      <text x="150" y="485" text-anchor="middle" font-size="12" fill="#065f46">Stratified squamous</text>
      <text x="150" y="500" text-anchor="middle" font-size="12" fill="#065f46">Normal differentiation</text>
    </g>
    <!-- HPV infection -->
    <g>
      <circle cx="150" cy="300" r="35" fill="#a855f7" stroke="#7c3aed"/>
      <text x="150" y="290" text-anchor="middle" font-size="14" font-weight="700" fill="#fff">HPV</text>
      <text x="150" y="305" text-anchor="middle" font-size="12" fill="#fff">16/18</text>
      <text x="150" y="320" text-anchor="middle" font-size="12" fill="#fff">High-risk</text>
    </g>
    <!-- Viral oncoproteins -->
    <g>
      <rect x="280" y="260" width="80" height="35" rx="8" fill="#fee2e2" stroke="#ef4444"/>
      <text x="320" y="282" text-anchor="middle" font-weight="700" fill="#991b1b">E6</text>
      <text x="320" y="295" text-anchor="middle" font-size="11" fill="#991b1b">degrades p53</text>
      <rect x="280" y="310" width="80" height="35" rx="8" fill="#fee2e2" stroke="#ef4444"/>
      <text x="320" y="332" text-anchor="middle" font-weight="700" fill="#991b1b">E7</text>
      <text x="320" y="345" text-anchor="middle" font-size="11" fill="#991b1b">disrupts pRb</text>
    </g>
    <!-- CIN progression -->
    <g>
      <rect x="420" y="400" width="160" height="120" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="500" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">CIN 1</text>
      <text x="500" y="445" text-anchor="middle" font-size="14" font-weight="700" fill="#92400e">Low-grade</text>
      <text x="500" y="465" text-anchor="middle" font-size="14" font-weight="700" fill="#92400e">dysplasia</text>
      <text x="500" y="485" text-anchor="middle" font-size="12" fill="#92400e">Mild cellular atypia</text>
      <text x="500" y="500" text-anchor="middle" font-size="12" fill="#92400e">Often regresses</text>
    </g>
    <g>
      <rect x="620" y="400" width="160" height="120" rx="12" fill="#fed7aa" stroke="#ea580c"/>
      <text x="700" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#9a3412">CIN 2/3</text>
      <text x="700" y="445" text-anchor="middle" font-size="14" font-weight="700" fill="#9a3412">High-grade</text>
      <text x="700" y="465" text-anchor="middle" font-size="14" font-weight="700" fill="#9a3412">dysplasia</text>
      <text x="700" y="485" text-anchor="middle" font-size="12" fill="#9a3412">Severe atypia</text>
      <text x="700" y="500" text-anchor="middle" font-size="12" fill="#9a3412">Precancerous</text>
    </g>
    <!-- Invasive carcinoma -->
    <g>
      <rect x="830" y="400" width="160" height="120" rx="12" fill="#fee2e2" stroke="#dc2626"/>
      <text x="910" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Invasive</text>
      <text x="910" y="445" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Squamous Cell</text>
      <text x="910" y="465" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Carcinoma</text>
      <text x="910" y="485" text-anchor="middle" font-size="12" fill="#991b1b">Basement membrane</text>
      <text x="910" y="500" text-anchor="middle" font-size="12" fill="#991b1b">invasion</text>
    </g>
    <!-- Model systems -->
    <g>
      <rect x="70" y="120" width="200" height="80" rx="12" fill="#e5e7eb" stroke="#6b7280"/>
      <text x="170" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#374151">Existing Mouse</text>
      <text x="170" y="165" text-anchor="middle" font-size="16" font-weight="700" fill="#374151">Models</text>
      <text x="170" y="185" text-anchor="middle" font-size="12" fill="#374151">TC-1, C3-Tag models</text>
    </g>
    <g>
      <rect x="320" y="120" width="250" height="80" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="445" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Novel Guinea Pig</text>
      <text x="445" y="165" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Cervical Cancer Model</text>
      <text x="445" y="185" text-anchor="middle" font-size="12" fill="#065f46">Enhanced human similarity</text>
    </g>
    <!-- Therapeutic vaccine -->
    <g>
      <rect x="620" y="120" width="200" height="120" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
      <text x="720" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#1d4ed8">E6/E7 Therapeutic</text>
      <text x="720" y="165" text-anchor="middle" font-size="16" font-weight="700" fill="#1d4ed8">Vaccine</text>
      <text x="720" y="185" text-anchor="middle" font-size="12" fill="#1d4ed8">Targets existing infections</text>
      <text x="720" y="200" text-anchor="middle" font-size="12" fill="#1d4ed8">CD8+ T cell responses</text>
      <text x="720" y="215" text-anchor="middle" font-size="12" fill="#1d4ed8">Tumor regression</text>
      <text x="720" y="230" text-anchor="middle" font-size="12" fill="#1d4ed8">Preventive immunity</text>
    </g>
    <!-- Immune responses -->
    <g>
      <rect x="870" y="120" width="200" height="120" rx="12" fill="#ecfdf5" stroke="#10b981"/>
      <text x="970" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Immune Response</text>
      <text x="970" y="165" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Activation</text>
      <text x="970" y="185" text-anchor="middle" font-size="12" fill="#065f46">CTL → E6/E7+ cells</text>
      <text x="970" y="200" text-anchor="middle" font-size="12" fill="#065f46">CD4+ Th1 help</text>
      <text x="970" y="215" text-anchor="middle" font-size="12" fill="#065f46">Memory formation</text>
      <text x="970" y="230" text-anchor="middle" font-size="12" fill="#065f46">Tumor clearance</text>
    </g>
    <!-- Arrows for progression -->
    <line x1="185" y1="318" x2="185" y2="400" stroke="#8b5cf6" stroke-width="4" marker-end="url(#arrPurple)"/>
    <text x="200" y="360" font-size="12" fill="#8b5cf6" font-weight="600">Infection</text>
    <line x1="280" y1="277" x2="240" y2="300" stroke="#ef4444" stroke-width="3"/>
    <text x="250" y="270" font-size="11" fill="#ef4444" font-weight="600">Oncoproteins</text>
    <line x1="230" y1="460" x2="420" y2="460" stroke="#f59e0b" stroke-width="4" marker-end="url(#arrOrange)"/>
    <text x="325" y="445" text-anchor="middle" font-size="12" fill="#f59e0b" font-weight="600">E6/E7 expression</text>
    <line x1="580" y1="460" x2="620" y2="460" stroke="#ea580c" stroke-width="4" marker-end="url(#arrOrange)"/>
    <line x1="780" y1="460" x2="830" y2="460" stroke="#dc2626" stroke-width="4" marker-end="url(#arrRedH)"/>
    <text x="805" y="445" text-anchor="middle" font-size="12" fill="#dc2626" font-weight="600">Progression</text>
    <!-- Vaccine intervention arrows -->
    <line x1="720" y1="240" x2="720" y2="280" stroke="#3b82f6" stroke-width="4" marker-end="url(#arrBlueH)"/>
    <path d="M 680 280 Q 650 320 620 460" stroke="#3b82f6" stroke-width="3" fill="none" stroke-dasharray="8,5"/>
    <path d="M 760 280 Q 790 320 830 460" stroke="#3b82f6" stroke-width="3" fill="none" stroke-dasharray="8,5"/>
    <text x="720" y="300" text-anchor="middle" font-size="12" fill="#3b82f6" font-weight="600">Therapeutic intervention</text>
    <!-- Model enhancement arrow -->
    <line x1="270" y1="160" x2="320" y2="160" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenH)"/>
    <text x="295" y="145" text-anchor="middle" font-size="11" fill="#10b981" font-weight="600">Enhanced</text>
    <text x="295" y="175" text-anchor="middle" font-size="11" fill="#10b981" font-weight="600">model</text>
    <!-- Immune activation -->
    <line x1="820" y1="180" x2="870" y2="180" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenH)"/>
    <!-- Summary box -->
    <g>
      <rect x="40" y="620" width="1100" height="70" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">Dual approach:</text>
      <text x="60" y="660" fill="#334155" font-size="12">Testing E6/E7 therapeutic vaccines in established mouse models (TC-1, C3-Tag) while developing novel syngeneic guinea pig cervical cancer models with enhanced physiological and immune similarity to humans for improved preclinical vaccine evaluation.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    HPV infection and E6/E7-driven progression from CIN to invasive cancer, with E6/E7-targeted therapeutic vaccination tested in mouse and novel guinea pig models.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 4: L2C / BTK -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>Syngeneic Guinea Pig Lymphoma Model for Therapeutic Development</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="L2C guinea pig lymphoma model with BCR-BTK signaling pathway and therapeutic testing">
    <defs>
      <marker id="arrBlueL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
      <marker id="arrRedL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrGreenL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <marker id="arrOrangeL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
      <marker id="arrPurpleL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
      <filter id="soft4"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">L2C Guinea Pig Lymphoma Model</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Syngeneic B-cell lymphoma → BCR–BTK signaling → NFκB survival → BTK inhibitor testing → Human disease modeling</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft4)"/>
    <!-- Normal B cell -->
    <g>
      <circle cx="150" cy="200" r="45" fill="#dcfce7" stroke="#10b981"/>
      <text x="150" y="190" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Normal</text>
      <text x="150" y="205" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">B Cell</text>
      <text x="150" y="220" text-anchor="middle" font-size="12" fill="#065f46">Controlled</text>
      <text x="150" y="235" text-anchor="middle" font-size="12" fill="#065f46">proliferation</text>
    </g>
    <!-- L2C lymphoma cell -->
    <g>
      <circle cx="400" cy="200" r="55" fill="#fecaca" stroke="#ef4444"/>
      <text x="400" y="185" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">L2C</text>
      <text x="400" y="205" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Lymphoma</text>
      <text x="400" y="225" text-anchor="middle" font-size="12" fill="#991b1b">Malignant B cells</text>
      <text x="400" y="240" text-anchor="middle" font-size="12" fill="#991b1b">Uncontrolled growth</text>
    </g>
    <!-- BCR signaling cascade -->
    <g>
      <rect x="320" y="120" width="160" height="60" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="400" y="140" text-anchor="middle" font-size="14" font-weight="700" fill="#075985">BCR Signaling Cascade</text>
      <rect x="330" y="150" width="50" height="25" rx="5" fill="#dbeafe" stroke="#3b82f6"/><text x="355" y="167" text-anchor="middle" font-size="11" font-weight="600" fill="#1d4ed8">BCR</text>
      <rect x="390" y="150" width="40" height="25" rx="5" fill="#fef3c7" stroke="#f59e0b"/><text x="410" y="167" text-anchor="middle" font-size="11" font-weight="600" fill="#92400e">BTK</text>
      <rect x="440" y="150" width="50" height="25" rx="5" fill="#fae8ff" stroke="#a855f7"/><text x="465" y="167" text-anchor="middle" font-size="10" font-weight="600" fill="#7c3aed">NFκB</text>
      <line x1="380" y1="163" x2="390" y2="163" stroke="#3b82f6" stroke-width="2" marker-end="url(#arrBlueL)"/>
      <line x1="430" y1="163" x2="440" y2="163" stroke="#f59e0b" stroke-width="2" marker-end="url(#arrOrangeL)"/>
    </g>
    <!-- Guinea pig in vivo model -->
    <g>
      <rect x="600" y="250" width="250" height="120" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="725" y="275" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Guinea Pig In Vivo Model</text>
      <text x="725" y="295" text-anchor="middle" font-size="13" fill="#065f46">• Syngeneic system (strain 2)</text>
      <text x="725" y="315" text-anchor="middle" font-size="13" fill="#065f46">• Immune competent</text>
      <text x="725" y="335" text-anchor="middle" font-size="13" fill="#065f46">• Tumor growth kinetics</text>
      <text x="725" y="355" text-anchor="middle" font-size="13" fill="#065f46">• Drug PK/PD studies</text>
    </g>
    <!-- Human disease analogs -->
    <g>
      <rect x="70" y="400" width="200" height="80" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
      <text x="170" y="425" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Mantle Cell</text>
      <text x="170" y="445" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Lymphoma (MCL)</text>
      <text x="170" y="465" text-anchor="middle" font-size="12" fill="#374151">BTK-dependent survival</text>
    </g>
    <g>
      <rect x="300" y="400" width="200" height="80" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
      <text x="400" y="425" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Chronic Lymphocytic</text>
      <text x="400" y="445" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Leukemia (CLL)</text>
      <text x="400" y="465" text-anchor="middle" font-size="12" fill="#374151">BCR addiction</text>
    </g>
    <!-- BTK inhibitors -->
    <g>
      <rect x="550" y="400" width="280" height="120" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
      <text x="690" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#1d4ed8">BTK Inhibitor Testing</text>
      <rect x="570" y="440" width="80" height="30" rx="8" fill="#bfdbfe" stroke="#3b82f6"/><text x="610" y="458" text-anchor="middle" font-size="11" font-weight="600" fill="#1d4ed8">Ibrutinib</text>
      <rect x="660" y="440" width="100" height="30" rx="8" fill="#bfdbfe" stroke="#3b82f6"/><text x="710" y="458" text-anchor="middle" font-size="11" font-weight="600" fill="#1d4ed8">Acalabrutinib</text>
      <rect x="570" y="480" width="80" height="30" rx="8" fill="#bfdbfe" stroke="#3b82f6"/><text x="610" y="498" text-anchor="middle" font-size="11" font-weight="600" fill="#1d4ed8">Zanubrutinib</text>
      <rect x="660" y="480" width="100" height="30" rx="8" fill="#bfdbfe" stroke="#3b82f6"/><text x="710" y="498" text-anchor="middle" font-size="10" font-weight="600" fill="#1d4ed8">Next-generation</text>
      <text x="780" y="455" text-anchor="middle" font-size="12" fill="#1d4ed8">Efficacy</text>
      <text x="780" y="470" text-anchor="middle" font-size="12" fill="#1d4ed8">Toxicity</text>
      <text x="780" y="485" text-anchor="middle" font-size="12" fill="#1d4ed8">Resistance</text>
      <text x="780" y="500" text-anchor="middle" font-size="12" fill="#1d4ed8">Biomarkers</text>
    </g>
    <!-- Single-cell analysis -->
    <g>
      <rect x="900" y="250" width="200" height="120" rx="12" fill="#faf5ff" stroke="#8b5cf6"/>
      <text x="1000" y="275" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">Single-cell Analysis</text>
      <text x="1000" y="295" text-anchor="middle" font-size="13" fill="#6b21a8">• scRNA-seq profiling</text>
      <text x="1000" y="315" text-anchor="middle" font-size="13" fill="#6b21a8">• Genomic characterization</text>
      <text x="1000" y="335" text-anchor="middle" font-size="13" fill="#6b21a8">• Pathway analysis</text>
      <text x="1000" y="355" text-anchor="middle" font-size="13" fill="#6b21a8">• Drug response signatures</text>
    </g>
    <!-- Transformation arrow -->
    <line x1="195" y1="200" x2="345" y2="200" stroke="#ef4444" stroke-width="4" marker-end="url(#arrRedL)"/>
    <text x="270" y="190" text-anchor="middle" font-size="12" fill="#ef4444" font-weight="600">Malignant transformation</text>
    <!-- Model inoculation -->
    <line x1="455" y1="200" x2="600" y2="280" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenL)"/>
    <text x="530" y="230" text-anchor="middle" font-size="11" fill="#10b981" font-weight="600">In vivo inoculation</text>
    <!-- Human disease modeling -->
    <path d="M 400 255 Q 300 350 170 400" stroke="#6b7280" stroke-width="3" fill="none" stroke-dasharray="8,5"/>
    <path d="M 400 255 Q 400 330 400 400" stroke="#6b7280" stroke-width="3" fill="none" stroke-dasharray="8,5"/>
    <text x="240" y="340" text-anchor="middle" font-size="11" fill="#6b7280" font-weight="600">Models human</text>
    <text x="240" y="355" text-anchor="middle" font-size="11" fill="#6b7280" font-weight="600">lymphomas</text>
    <!-- Therapeutic testing -->
    <line x1="690" y1="370" x2="690" y2="400" stroke="#3b82f6" stroke-width="4" marker-end="url(#arrBlueL)"/>
    <text x="720" y="385" font-size="12" fill="#3b82f6" font-weight="600">Drug testing</text>
    <!-- Analysis connection -->
    <line x1="850" y1="310" x2="900" y2="310" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurpleL)"/>
    <text x="875" y="300" text-anchor="middle" font-size="11" fill="#8b5cf6" font-weight="600">Molecular</text>
    <text x="875" y="325" text-anchor="middle" font-size="11" fill="#8b5cf6" font-weight="600">profiling</text>
    <!-- BCR signaling connection -->
    <line x1="400" y1="180" x2="400" y2="145" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlueL)"/>
    <!-- Summary box -->
    <g>
      <rect x="40" y="620" width="1100" height="70" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">L2C Model advantages:</text>
      <text x="60" y="660" fill="#334155" font-size="12">Syngeneic guinea pig B-cell lymphoma with BCR→BTK→NFκB signaling addiction, enabling BTK inhibitor pharmacology studies. Single-cell genomics positions L2C as analog for human MCL and CLL, providing immune-competent preclinical testing platform.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    L2C model with BCR→BTK→NFκB signaling, single-cell profiling, and BTK inhibitor pharmacology; benchmarked to MCL/CLL.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 5: Adaptation -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>Comparative Virology and Host Adaptation Engineering</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Comparative virology using related viruses to engineer guinea pig-adapted strains">
    <defs>
      <marker id="arrBlueA" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
      <marker id="arrRedA" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrGreenA" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <marker id="arrOrangeA" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
      <marker id="arrPurpleA" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
      <filter id="soft5"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Comparative Virology & Host Adaptation Engineering</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Human viruses → Related animal viruses → Adaptation mechanisms → Engineered guinea pig-adapted strains</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft5)"/>
    <!-- Human-restricted viruses -->
    <g>
      <text x="170" y="120" text-anchor="middle" font-size="18" font-weight="700" fill="#0f172a">Human-Restricted Viruses</text>
      <circle cx="120" cy="180" r="40" fill="#fecaca" stroke="#ef4444"/>
      <text x="120" y="170" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">KSHV</text>
      <text x="120" y="185" text-anchor="middle" font-size="12" fill="#991b1b">HHV-8</text>
      <text x="120" y="200" text-anchor="middle" font-size="12" fill="#991b1b">Human only</text>
      <circle cx="220" cy="180" r="40" fill="#fecaca" stroke="#ef4444"/>
      <text x="220" y="170" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">EBV</text>
      <text x="220" y="185" text-anchor="middle" font-size="12" fill="#991b1b">HHV-4</text>
      <text x="220" y="200" text-anchor="middle" font-size="12" fill="#991b1b">Primate-restricted</text>
    </g>
    <!-- Related animal viruses -->
    <g>
      <text x="170" y="340" text-anchor="middle" font-size="18" font-weight="700" fill="#0f172a">Related Animal Viruses</text>
      <circle cx="90" cy="400" r="35" fill="#fed7aa" stroke="#f59e0b"/>
      <text x="90" y="390" text-anchor="middle" font-size="12" font-weight="700" fill="#92400e">RRV</text>
      <text x="90" y="405" text-anchor="middle" font-size="11" fill="#92400e">Rhesus</text>
      <text x="90" y="420" text-anchor="middle" font-size="11" fill="#92400e">rhadinovirus</text>
      <circle cx="170" cy="400" r="35" fill="#fed7aa" stroke="#f59e0b"/>
      <text x="170" y="390" text-anchor="middle" font-size="12" font-weight="700" fill="#92400e">GPHLV</text>
      <text x="170" y="405" text-anchor="middle" font-size="10" fill="#92400e">Guinea pig</text>
      <text x="170" y="420" text-anchor="middle" font-size="10" fill="#92400e">herpes-like</text>
      <circle cx="250" cy="400" r="35" fill="#fed7aa" stroke="#f59e0b"/>
      <text x="250" y="390" text-anchor="middle" font-size="12" font-weight="700" fill="#92400e">GPXV</text>
      <text x="250" y="405" text-anchor="middle" font-size="10" fill="#92400e">Guinea pig</text>
      <text x="250" y="420" text-anchor="middle" font-size="10" fill="#92400e">cytomegalovirus</text>
    </g>
    <!-- Adaptation engineering process -->
    <g>
      <rect x="400" y="180" width="300" height="180" rx="12" fill="#f3e8ff" stroke="#8b5cf6"/>
      <text x="550" y="205" text-anchor="middle" font-size="18" font-weight="700" fill="#6b21a8">Adaptation Engineering</text>
      <rect x="420" y="220" width="260" height="50" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="550" y="240" text-anchor="middle" font-size="14" font-weight="700" fill="#6b21a8">Key Adaptation Factors:</text>
      <text x="550" y="255" text-anchor="middle" font-size="12" fill="#6b21a8">• Receptor binding domains</text>
      <text x="550" y="270" text-anchor="middle" font-size="12" fill="#6b21a8">• Species-specific immune evasion</text>
      <rect x="420" y="285" width="125" height="60" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="482" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#6b21a8">Host Tropism</text>
      <text x="482" y="320" text-anchor="middle" font-size="11" fill="#6b21a8">• Cell surface receptors</text>
      <text x="482" y="335" text-anchor="middle" font-size="11" fill="#6b21a8">• Entry mechanisms</text>
      <rect x="555" y="285" width="125" height="60" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="617" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#6b21a8">Immune Evasion</text>
      <text x="617" y="320" text-anchor="middle" font-size="11" fill="#6b21a8">• Species-specific vIRFs</text>
      <text x="617" y="335" text-anchor="middle" font-size="11" fill="#6b21a8">• miRNA seed matches</text>
    </g>
    <!-- Guinea pig-adapted viruses -->
    <g>
      <text x="950" y="120" text-anchor="middle" font-size="18" font-weight="700" fill="#0f172a">Guinea Pig-Adapted Strains</text>
      <circle cx="900" cy="180" r="40" fill="#dcfce7" stroke="#10b981"/>
      <text x="900" y="165" text-anchor="middle" font-size="12" font-weight="700" fill="#065f46">KSHV</text>
      <text x="900" y="180" text-anchor="middle" font-size="12" font-weight="700" fill="#065f46">(GP-adapted)</text>
      <text x="900" y="195" text-anchor="middle" font-size="10" fill="#065f46">Engineered</text>
      <text x="900" y="208" text-anchor="middle" font-size="10" fill="#065f46">strain</text>
      <circle cx="1000" cy="180" r="40" fill="#dcfce7" stroke="#10b981"/>
      <text x="1000" y="165" text-anchor="middle" font-size="12" font-weight="700" fill="#065f46">EBV</text>
      <text x="1000" y="180" text-anchor="middle" font-size="12" font-weight="700" fill="#065f46">(GP-adapted)</text>
      <text x="1000" y="195" text-anchor="middle" font-size="10" fill="#065f46">Engineered</text>
      <text x="1000" y="208" text-anchor="middle" font-size="10" fill="#065f46">strain</text>
    </g>
    <!-- Guinea pig host system -->
    <g>
      <rect x="800" y="280" width="280" height="120" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="940" y="305" text-anchor="middle" font-size="18" font-weight="700" fill="#065f46">Guinea Pig Host System</text>
      <text x="940" y="325" text-anchor="middle" font-size="13" fill="#065f46">• Immune competent</text>
      <text x="940" y="345" text-anchor="middle" font-size="13" fill="#065f46">• Physiologically relevant</text>
      <text x="940" y="365" text-anchor="middle" font-size="13" fill="#065f46">• Enhanced human similarity</text>
      <text x="940" y="385" text-anchor="middle" font-size="13" fill="#065f46">• Viral pathogenesis studies</text>
    </g>
    <!-- Validation studies -->
    <g>
      <rect x="400" y="450" width="300" height="80" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="550" y="475" text-anchor="middle" font-size="16" font-weight="700" fill="#075985">In Vivo Validation</text>
      <text x="550" y="495" text-anchor="middle" font-size="13" fill="#075985">• Infection kinetics</text>
      <text x="550" y="510" text-anchor="middle" font-size="13" fill="#075985">• Pathogenesis patterns</text>
      <text x="550" y="525" text-anchor="middle" font-size="13" fill="#075985">• Immune responses</text>
    </g>
    <!-- Arrows showing adaptation process -->
    <line x1="280" y1="180" x2="400" y2="180" stroke="#8b5cf6" stroke-width="4" marker-end="url(#arrPurpleA)"/>
    <text x="340" y="170" text-anchor="middle" font-size="12" fill="#8b5cf6" font-weight="600">Comparative analysis</text>
    <line x1="700" y1="180" x2="860" y2="180" stroke="#10b981" stroke-width="4" marker-end="url(#arrGreenA)"/>
    <text x="780" y="170" text-anchor="middle" font-size="12" fill="#10b981" font-weight="600">Engineering</text>
    <!-- Related virus input -->
    <path d="M 170 365 Q 300 320 400 280" stroke="#f59e0b" stroke-width="3" fill="none" stroke-dasharray="8,5"/>
    <text x="280" y="330" text-anchor="middle" font-size="11" fill="#f59e0b" font-weight="600">Adaptation insights</text>
    <!-- Host system connection -->
    <line x1="950" y1="220" x2="950" y2="280" stroke="#10b981" stroke-width="4" marker-end="url(#arrGreenA)"/>
    <text x="970" y="250" font-size="12" fill="#10b981" font-weight="600">Testing</text>
    <!-- Validation connection -->
    <line x1="550" y1="360" x2="550" y2="450" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlueA)"/>
    <text x="570" y="405" font-size="12" fill="#0ea5e9" font-weight="600">Validate</text>
    <!-- Cross-validation -->
    <path d="M 800 340 Q 700 400 600 450" stroke="#0ea5e9" stroke-width="3" fill="none" stroke-dasharray="5,3"/>
    <text x="700" y="380" text-anchor="middle" font-size="11" fill="#0ea5e9" font-weight="600">Pathogenesis validation</text>
    <!-- Summary box -->
    <g>
      <rect x="40" y="620" width="1100" height="70" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">Comparative approach:</text>
      <text x="60" y="660" fill="#334155" font-size="12">Studying RRV, guinea pig herpes-like viruses (GPHLV), and guinea pig cytomegalovirus (GPXV) to understand host adaptation mechanisms. Engineering guinea pig-adapted KSHV and EBV strains by modifying receptor binding and immune evasion genes, validated through in vivo pathogenesis studies.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    Using related herpesviruses to guide engineering of guinea pig–adapted strains and validate tropism and pathogenesis in vivo.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 6: Preclinical Platform -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>Comprehensive Preclinical Testing Platform</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Multi-modal therapeutic testing platform across viral cancer models">
    <defs>
      <marker id="arrBluePCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
      <marker id="arrRedPCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrGreenPCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <marker id="arrOrangePCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
      <marker id="arrPurplePCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
      <marker id="arrGrayPCL" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#6b7280"/></marker>
      <filter id="soft6"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Comprehensive Preclinical Testing Platform</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Multi-modal therapeutic evaluation across guinea pig viral cancer models with standardized outcomes</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft6)"/>
    
    <!-- Central guinea pig models hub -->
    <g>
      <ellipse cx="590" cy="300" rx="130" ry="90" fill="#dcfce7" stroke="#10b981" stroke-width="4"/>
      <text x="590" y="275" text-anchor="middle" font-size="18" font-weight="700" fill="#065f46">Guinea Pig</text>
      <text x="590" y="295" text-anchor="middle" font-size="18" font-weight="700" fill="#065f46">Cancer Models</text>
      <text x="590" y="315" text-anchor="middle" font-size="13" fill="#065f46">• KSHV/EBV-associated</text>
      <text x="590" y="335" text-anchor="middle" font-size="13" fill="#065f46">• HPV cervical cancer</text>
      <text x="590" y="355" text-anchor="middle" font-size="13" fill="#065f46">• L2C lymphoma</text>
    </g>

    <!-- Therapeutic categories around the center -->
    <!-- Antivirals (top left) -->
    <g>
      <rect x="120" y="120" width="180" height="100" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
      <text x="210" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#1d4ed8">Antivirals</text>
      <text x="210" y="165" text-anchor="middle" font-size="13" fill="#1d4ed8">• Nucleoside analogs</text>
      <text x="210" y="180" text-anchor="middle" font-size="13" fill="#1d4ed8">• Protease inhibitors</text>
      <text x="210" y="195" text-anchor="middle" font-size="13" fill="#1d4ed8">• Entry inhibitors</text>
      <text x="210" y="210" text-anchor="middle" font-size="13" fill="#1d4ed8">• Polymerase inhibitors</text>
    </g>

    <!-- Vaccines (top center) -->
    <g>
      <rect x="350" y="120" width="180" height="100" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="440" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Therapeutic Vaccines</text>
      <text x="440" y="165" text-anchor="middle" font-size="13" fill="#92400e">• E6/E7 targeting</text>
      <text x="440" y="180" text-anchor="middle" font-size="13" fill="#92400e">• KSHV latency antigens</text>
      <text x="440" y="195" text-anchor="middle" font-size="13" fill="#92400e">• DNA/peptide vaccines</text>
      <text x="440" y="210" text-anchor="middle" font-size="13" fill="#92400e">• Viral vector delivery</text>
    </g>

    <!-- Live-attenuated vaccines (top right) -->
    <g>
      <rect x="580" y="120" width="180" height="100" rx="12" fill="#fae8ff" stroke="#8b5cf6"/>
      <text x="670" y="140" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">Live-attenuated</text>
      <text x="670" y="160" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">Vaccines</text>
      <text x="670" y="180" text-anchor="middle" font-size="13" fill="#6b21a8">• Oncolytic viruses</text>
      <text x="670" y="195" text-anchor="middle" font-size="13" fill="#6b21a8">• Immune modulators</text>
      <text x="670" y="210" text-anchor="middle" font-size="13" fill="#6b21a8">• Adjuvant systems</text>
    </g>

    <!-- Epigenetic modulators (right) -->
    <g>
      <rect x="880" y="200" width="180" height="100" rx="12" fill="#fee2e2" stroke="#ef4444"/>
      <text x="970" y="225" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Epigenetic</text>
      <text x="970" y="245" text-anchor="middle" font-size="16" font-weight="700" fill="#991b1b">Modulators</text>
      <text x="970" y="265" text-anchor="middle" font-size="13" fill="#991b1b">• HDAC inhibitors</text>
      <text x="970" y="280" text-anchor="middle" font-size="13" fill="#991b1b">• G-quadruplex stabilizers</text>
      <text x="970" y="295" text-anchor="middle" font-size="13" fill="#991b1b">• DNA methylation</text>
    </g>

    <!-- Targeted therapies (bottom right) -->
    <g>
      <rect x="880" y="380" width="180" height="100" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="970" y="405" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Targeted</text>
      <text x="970" y="425" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Therapies</text>
      <text x="970" y="445" text-anchor="middle" font-size="13" fill="#065f46">• BTK inhibitors</text>
      <text x="970" y="460" text-anchor="middle" font-size="13" fill="#065f46">• PI3K/mTOR inhibitors</text>
      <text x="970" y="475" text-anchor="middle" font-size="13" fill="#065f46">• Kinase inhibitors</text>
    </g>

    <!-- Immunotherapies (bottom center) -->
    <g>
      <rect x="350" y="480" width="180" height="100" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
      <text x="440" y="505" text-anchor="middle" font-size="16" font-weight="700" fill="#374151">Immunotherapies</text>
      <text x="440" y="525" text-anchor="middle" font-size="13" fill="#374151">• Checkpoint inhibitors</text>
      <text x="440" y="540" text-anchor="middle" font-size="13" fill="#374151">• Adoptive cell therapy</text>
      <text x="440" y="555" text-anchor="middle" font-size="13" fill="#374151">• Cytokine modulators</text>
      <text x="440" y="570" text-anchor="middle" font-size="13" fill="#374151">• Monoclonal antibodies</text>
    </g>

    <!-- Combination therapies (bottom left) -->
    <g>
      <rect x="120" y="480" width="180" height="100" rx="12" fill="#fef3c7" stroke="#d97706"/>
      <text x="210" y="505" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Combination</text>
      <text x="210" y="525" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Therapies</text>
      <text x="210" y="545" text-anchor="middle" font-size="13" fill="#92400e">• Multi-target approaches</text>
      <text x="210" y="560" text-anchor="middle" font-size="13" fill="#92400e">• Synergistic effects</text>
      <text x="210" y="575" text-anchor="middle" font-size="13" fill="#92400e">• Sequential dosing</text>
    </g>

    <!-- Arrows pointing to center -->
    <line x1="300" y1="170" x2="460" y2="240" stroke="#3b82f6" stroke-width="3" marker-end="url(#arrBluePCL)"/>
    <line x1="440" y1="220" x2="520" y2="260" stroke="#f59e0b" stroke-width="3" marker-end="url(#arrOrangePCL)"/>
    <line x1="670" y1="220" x2="650" y2="260" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurplePCL)"/>
    <line x1="880" y1="250" x2="720" y2="280" stroke="#ef4444" stroke-width="3" marker-end="url(#arrRedPCL)"/>
    <line x1="880" y1="430" x2="720" y2="360" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenPCL)"/>
    <line x1="440" y1="480" x2="520" y2="360" stroke="#6b7280" stroke-width="3" marker-end="url(#arrGrayPCL)"/>
    <line x1="300" y1="530" x2="460" y2="360" stroke="#d97706" stroke-width="3" marker-end="url(#arrOrangePCL)"/>

    <!-- Outcome measures -->
    <g>
      <rect x="120" y="320" width="180" height="120" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="210" y="345" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Outcome Measures</text>
      <text x="210" y="365" text-anchor="middle" font-size="13" fill="#334155">• Viral load reduction</text>
      <text x="210" y="380" text-anchor="middle" font-size="13" fill="#334155">• Tumor burden</text>
      <text x="210" y="395" text-anchor="middle" font-size="13" fill="#334155">• Survival endpoints</text>
      <text x="210" y="410" text-anchor="middle" font-size="13" fill="#334155">• Immune activation</text>
      <text x="210" y="425" text-anchor="middle" font-size="13" fill="#334155">• Safety/toxicity</text>
    </g>

    <!-- Connection to outcomes -->
    <line x1="460" y1="340" x2="300" y2="360" stroke="#cbd5e1" stroke-width="2" stroke-dasharray="5,5"/>

    <!-- Summary box -->
    <g>
      <rect x="40" y="620" width="1100" height="60" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">Platform integration:</text>
      <text x="60" y="660" fill="#334155" font-size="12">Comprehensive therapeutic evaluation across antivirals, vaccines, epigenetic modulators, targeted and immune therapies using guinea pig viral cancer models. Standardized outcome measures enable cross-platform comparison and translational relevance to human disease.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    Integrated testing of antivirals, vaccines, epigenetic modulators, targeted and immune therapies across guinea pig and mouse models with harmonized outcomes.
  </div>
</figure>

<!-- ======================================== -->
<!-- Diagram 7: Single-cell & Systems -->
<!-- ======================================== -->
<figure class="research-graphic fade-in">
  <h3>Single-cell Genomics and Systems Biology Approaches</h3>
  <svg class="static-svg" viewBox="0 0 1180 700" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Single-cell RNA sequencing workflow from tissue to pathway analysis">
    <defs>
      <marker id="arrBlueSC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
      <marker id="arrRedSC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrGreenSC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
      <marker id="arrOrangeSC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
      <marker id="arrPurpleSC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
      <marker id="arrGraySC" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#6b7280"/></marker>
      <filter id="soft7"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
    </defs>
    <text x="590" y="36" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Single-cell Genomics & Systems Biology</text>
    <text x="590" y="62" text-anchor="middle" font-size="14" fill="#64748b">Tissue dissociation → scRNA-seq → Cell type identification → Pathway analysis → Systems integration</text>
    <rect x="40" y="80" width="1100" height="520" rx="20" fill="#ffffff" stroke="#e2e8f0" filter="url(#soft7)"/>
    
    <!-- Tissue sample -->
    <g>
      <rect x="80" y="150" width="140" height="100" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
      <text x="150" y="175" text-anchor="middle" font-size="16" font-weight="700" fill="#374151">Tumor Tissue</text>
      <text x="150" y="195" text-anchor="middle" font-size="13" fill="#374151">Mixed cell populations:</text>
      <text x="150" y="210" text-anchor="middle" font-size="12" fill="#374151">• Tumor cells</text>
      <text x="150" y="225" text-anchor="middle" font-size="12" fill="#374151">• Immune cells</text>
      <text x="150" y="240" text-anchor="middle" font-size="12" fill="#374151">• Stromal cells</text>
    </g>

    <!-- Single-cell dissociation -->
    <g>
      <text x="320" y="130" text-anchor="middle" font-size="14" font-weight="700" fill="#0f172a">Single Cell Dissociation</text>
      <circle cx="290" cy="160" r="12" fill="#10b981" stroke="#059669"/>
      <circle cx="320" cy="180" r="12" fill="#ef4444" stroke="#dc2626"/>
      <circle cx="270" cy="200" r="12" fill="#3b82f6" stroke="#1d4ed8"/>
      <circle cx="340" cy="190" r="12" fill="#f59e0b" stroke="#d97706"/>
      <circle cx="310" cy="220" r="12" fill="#8b5cf6" stroke="#7c3aed"/>
      <circle cx="350" cy="170" r="12" fill="#6b7280" stroke="#4b5563"/>
      <circle cx="280" cy="240" r="12" fill="#14b8a6" stroke="#0d9488"/>
    </g>

    <!-- 10X Genomics workflow -->
    <g>
      <rect x="420" y="150" width="140" height="100" rx="12" fill="#fae8ff" stroke="#8b5cf6"/>
      <text x="490" y="175" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">10X Genomics</text>
      <text x="490" y="195" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">scRNA-seq</text>
      <text x="490" y="215" text-anchor="middle" font-size="12" fill="#6b21a8">• Cell barcoding</text>
      <text x="490" y="230" text-anchor="middle" font-size="12" fill="#6b21a8">• UMI counting</text>
      <text x="490" y="245" text-anchor="middle" font-size="12" fill="#6b21a8">• High throughput</text>
    </g>

    <!-- Data analysis pipeline -->
    <g>
      <rect x="620" y="120" width="200" height="160" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="720" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#075985">Data Analysis Pipeline</text>
      
      <rect x="640" y="160" width="80" height="30" rx="6" fill="#bae6fd" stroke="#0ea5e9"/>
      <text x="680" y="178" text-anchor="middle" font-size="11" font-weight="600" fill="#075985">QC & Filtering</text>
      
      <rect x="730" y="160" width="80" height="30" rx="6" fill="#bae6fd" stroke="#0ea5e9"/>
      <text x="770" y="178" text-anchor="middle" font-size="11" font-weight="600" fill="#075985">Normalization</text>
      
      <rect x="640" y="200" width="80" height="30" rx="6" fill="#bae6fd" stroke="#0ea5e9"/>
      <text x="680" y="218" text-anchor="middle" font-size="11" font-weight="600" fill="#075985">Clustering</text>
      
      <rect x="730" y="200" width="80" height="30" rx="6" fill="#bae6fd" stroke="#0ea5e9"/>
      <text x="770" y="218" text-anchor="middle" font-size="11" font-weight="600" fill="#075985">t-SNE/UMAP</text>
      
      <rect x="640" y="240" width="160" height="30" rx="6" fill="#bae6fd" stroke="#0ea5e9"/>
      <text x="720" y="258" text-anchor="middle" font-size="11" font-weight="600" fill="#075985">Cell Type Identification</text>
    </g>

    <!-- Cell type results -->
    <g>
      <rect x="880" y="120" width="180" height="160" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="970" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Cell Type Clusters</text>
      
      <circle cx="920" cy="170" r="10" fill="#ef4444" stroke="#dc2626"/>
      <text x="950" y="175" font-size="12" fill="#065f46">Tumor cells</text>
      
      <circle cx="920" cy="190" r="10" fill="#3b82f6" stroke="#1d4ed8"/>
      <text x="950" y="195" font-size="12" fill="#065f46">CD8+ T cells</text>
      
      <circle cx="920" cy="210" r="10" fill="#f59e0b" stroke="#d97706"/>
      <text x="950" y="215" font-size="12" fill="#065f46">CD4+ T cells</text>
      
      <circle cx="920" cy="230" r="10" fill="#8b5cf6" stroke="#7c3aed"/>
      <text x="950" y="235" font-size="12" fill="#065f46">B cells</text>
      
      <circle cx="920" cy="250" r="10" fill="#6b7280" stroke="#4b5563"/>
      <text x="950" y="255" font-size="12" fill="#065f46">Macrophages</text>
      
      <circle cx="920" cy="270" r="10" fill="#14b8a6" stroke="#0d9488"/>
      <text x="950" y="275" font-size="12" fill="#065f46">Fibroblasts</text>
    </g>

    <!-- Pathway analysis -->
    <g>
      <rect x="80" y="350" width="200" height="120" rx="12" fill="#fff7ed" stroke="#fb923c"/>
      <text x="180" y="375" text-anchor="middle" font-size="16" font-weight="700" fill="#9a3412">Pathway Analysis</text>
      <text x="180" y="395" text-anchor="middle" font-size="13" fill="#9a3412">• GSEA enrichment</text>
      <text x="180" y="410" text-anchor="middle" font-size="13" fill="#9a3412">• Viral gene programs</text>
      <text x="180" y="425" text-anchor="middle" font-size="13" fill="#9a3412">• Host immune responses</text>
      <text x="180" y="440" text-anchor="middle" font-size="13" fill="#9a3412">• Cell-cell communication</text>
      <text x="180" y="455" text-anchor="middle" font-size="13" fill="#9a3412">• Drug target prediction</text>
    </g>

    <!-- Spatial validation -->
    <g>
      <rect x="320" y="350" width="200" height="120" rx="12" fill="#ecfdf5" stroke="#10b981"/>
      <text x="420" y="375" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Spatial Validation</text>
      <text x="420" y="395" text-anchor="middle" font-size="13" fill="#065f46">• Immunohistochemistry</text>
      <text x="420" y="410" text-anchor="middle" font-size="13" fill="#065f46">• In situ hybridization</text>
      <text x="420" y="425" text-anchor="middle" font-size="13" fill="#065f46">• Spatial transcriptomics</text>
      <text x="420" y="440" text-anchor="middle" font-size="13" fill="#065f46">• Tissue architecture</text>
      <text x="420" y="455" text-anchor="middle" font-size="13" fill="#065f46">• Biomarker validation</text>
    </g>

    <!-- Systems integration -->
    <g>
      <rect x="580" y="350" width="200" height="120" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="680" y="375" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Systems Integration</text>
      <text x="680" y="395" text-anchor="middle" font-size="13" fill="#92400e">• Multi-omics analysis</text>
      <text x="680" y="410" text-anchor="middle" font-size="13" fill="#92400e">• Network modeling</text>
      <text x="680" y="425" text-anchor="middle" font-size="13" fill="#92400e">• Regulatory circuits</text>
      <text x="680" y="440" text-anchor="middle" font-size="13" fill="#92400e">• Drug synergy prediction</text>
      <text x="680" y="455" text-anchor="middle" font-size="13" fill="#92400e">• Biomarker discovery</text>
    </g>

    <!-- Disease models -->
    <g>
      <rect x="840" y="350" width="220" height="120" rx="12" fill="#f3e8ff" stroke="#8b5cf6"/>
      <text x="950" y="375" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">Disease Model Applications</text>
      
      <rect x="860" y="390" width="60" height="25" rx="5" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="890" y="405" text-anchor="middle" font-size="10" font-weight="600" fill="#6b21a8">KSHV KS</text>
      
      <rect x="930" y="390" width="60" height="25" rx="5" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="960" y="405" text-anchor="middle" font-size="10" font-weight="600" fill="#6b21a8">HPV CxCa</text>
      
      <rect x="1000" y="390" width="50" height="25" rx="5" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="1025" y="405" text-anchor="middle" font-size="10" font-weight="600" fill="#6b21a8">L2C</text>
      
      <rect x="860" y="425" width="60" height="25" rx="5" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="890" y="440" text-anchor="middle" font-size="10" font-weight="600" fill="#6b21a8">EBV</text>
      
      <rect x="930" y="425" width="110" height="25" rx="5" fill="#ede9fe" stroke="#8b5cf6"/>
      <text x="985" y="440" text-anchor="middle" font-size="10" font-weight="600" fill="#6b21a8">Therapeutic testing</text>
    </g>

    <!-- Flow arrows -->
    <line x1="220" y1="200" x2="270" y2="200" stroke="#6b7280" stroke-width="3" marker-end="url(#arrGraySC)"/>
    <text x="245" y="190" text-anchor="middle" font-size="11" fill="#6b7280" font-weight="600">Dissociate</text>

    <line x1="360" y1="200" x2="420" y2="200" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurpleSC)"/>
    <text x="390" y="190" text-anchor="middle" font-size="11" fill="#8b5cf6" font-weight="600">Sequence</text>

    <line x1="560" y1="200" x2="620" y2="200" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlueSC)"/>
    <text x="590" y="190" text-anchor="middle" font-size="11" fill="#0ea5e9" font-weight="600">Analyze</text>

    <line x1="820" y1="200" x2="880" y2="200" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenSC)"/>
    <text x="850" y="190" text-anchor="middle" font-size="11" fill="#10b981" font-weight="600">Identify</text>

    <!-- Analysis connections -->
    <line x1="720" y1="280" x2="180" y2="350" stroke="#fb923c" stroke-width="3" marker-end="url(#arrOrangeSC)"/>
    <line x1="720" y1="280" x2="420" y2="350" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreenSC)"/>
    <line x1="720" y1="280" x2="680" y2="350" stroke="#f59e0b" stroke-width="3" marker-end="url(#arrOrangeSC)"/>
    <line x1="820" y1="250" x2="950" y2="350" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurpleSC)"/>

    <!-- Cross-validation arrows -->
    <path d="M 280 410 Q 350 320 420 350" stroke="#10b981" stroke-width="2" fill="none" stroke-dasharray="5,3"/>
    <path d="M 520 410 Q 600 320 680 350" stroke="#f59e0b" stroke-width="2" fill="none" stroke-dasharray="5,3"/>

    <!-- Summary box -->
    <g>
      <rect x="40" y="620" width="1100" height="60" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
      <text x="60" y="642" font-weight="700" fill="#0f172a">Integrated workflow:</text>
      <text x="60" y="660" fill="#334155" font-size="12">From tissue dissociation to t-SNE clustering and pathway programs, linked to histology/IHC for spatial validation and biomarker discovery across KSHV, HPV, and lymphoma models with therapeutic response profiling.</text>
    </g>
  </svg>
  <div class="diagram-caption">
    From tissue dissociation to t-SNE clustering and pathway programs, linked to histology/IHC for spatial validation and biomarker discovery.
  </div>
</figure>

<p class="fade-in">
  Together, these efforts define a comprehensive program in <strong>viral oncology</strong>:
  connecting molecular mechanisms of viral pathogenesis to clinically relevant animal models
  across herpesvirus and papillomavirus systems. By expanding the guinea pig as a small-animal
  model for KSHV/EBV-associated cancers and HPV cervical cancer, we aim to deliver practical
  tools for understanding—and ultimately intervening in—the full spectrum of virus-associated cancers.
</p>
```

  </main>

  <footer class="site-footer" role="contentinfo">
    <div class="container footer-grid">
      <div class="footer-brand">
        <img src="assets/stanfield-lab-icon.svg" alt="Stanfield Lab icon" class="footer-logo">
        <div>
          <h3>Stanfield Lab</h3>
          <p>Viral Oncology • Guinea-pig models of virus-associated cancers</p>
        </div>
      </div>
      <div>
        <h4>Find us</h4>
        <p>
          <a href="https://www.lsu.edu/vetmed/index.php" target="_blank" rel="noopener">LSU School of Veterinary Medicine</a><br>
          Baton Rouge, LA 70803
        </p>
      </div>
      <div>
        <h4>Contact</h4>
        <p><a href="mailto:bstanf5@lsu.edu">bstanf5@lsu.edu</a></p>
      </div>
    </div>
    <div class="container footer-bottom">
      <p>© <span id="year"></span> Stanfield Lab • LSU SVM</p>
    </div>
  </footer>

  <script>
    // Mobile navigation
    document.getElementById('navToggle').addEventListener('click', function() {
      const nav = document.getElementById('primaryNav');
      const isExpanded = this.getAttribute('aria-expanded') === 'true';
      this.setAttribute('aria-expanded', !isExpanded);
      nav.classList.toggle('active');
    });

    // Simple scroll animation
    function handleScrollAnimation() {
      const elements = document.querySelectorAll('.fade-in');
      elements.forEach(el => {
        const top = el.getBoundingClientRect().top;
        if (top < window.innerHeight - 150) el.classList.add('visible');
      });
    }
    window.addEventListener('scroll', handleScrollAnimation);
    handleScrollAnimation();

    // Year
    document.getElementById('year').textContent = new Date().getFullYear();

    // Theme toggle placeholder
    document.getElementById('themeToggle').addEventListener('click', function() {
      document.documentElement.classList.toggle('dark');
    });
  </script>

</body>
</html>
